{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:56:44Z","timestamp":1776261404629,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.metabol.2013.05.001","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T15:31:07Z","timestamp":1372951867000},"page":"1330-1339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes"],"prefix":"10.1016","volume":"62","author":[{"given":"Amalia","family":"Gastaldelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Nauck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Balena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.metabol.2013.05.001_bb0005","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1210\/en.2009-1459","article-title":"Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency","volume":"151","author":"Sebokova","year":"2010","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.metabol.2013.05.001_bb0010","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1464-5491.2009.02854.x","article-title":"Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes","volume":"26","author":"Kapitza","year":"2009","journal-title":"Diabet Med"},{"issue":"7","key":"10.1016\/j.metabol.2013.05.001_bb0015","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2337\/dc08-1961","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.metabol.2013.05.001_bb0020","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1210\/jc.2011-3253","article-title":"Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24weeks: T-Emerge 3 trial","volume":"97","author":"Henry","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2013.05.001_bb0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/oby.20042","article-title":"Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study)","volume":"21","author":"Hollander","year":"2013","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.metabol.2013.05.001_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/dme.12003","article-title":"Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with type 2 diabetes: an open-label randomized trial","volume":"30","author":"Nauck","year":"2013","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.metabol.2013.05.001_bb0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/dom.12009","article-title":"Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6)","volume":"15","author":"Pratley","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.metabol.2013.05.001_bb0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13300-012-0013-8","article-title":"Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial)","volume":"3","author":"Bergenstal","year":"2012","journal-title":"Diabet Ther"},{"issue":"3","key":"10.1016\/j.metabol.2013.05.001_bb0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2337\/dc11-1942","article-title":"Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)","volume":"35","author":"Raz","year":"2012","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.metabol.2013.05.001_bb0050","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2337\/dc12-0709","article-title":"The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.metabol.2013.05.001_bb0055","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly glucagon-like peptide-1 receptor agonists\u2014available efficacy and safety data and perspectives for the future","volume":"13","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.metabol.2013.05.001_bb0060","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1185\/03007990802418851","article-title":"Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study","volume":"24","author":"DeFronzo","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"17","key":"10.1016\/j.metabol.2013.05.001_bb0065","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2165\/11208110-000000000-00000","article-title":"Liraglutide: a review of its use in the management of type 2 diabetes mellitus","volume":"71","author":"Perry","year":"2011","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.metabol.2013.05.001_bb0070","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/13543784.2011.562191","article-title":"Lixisenatide for type 2 diabetes mellitus","volume":"20","author":"Christensen","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.metabol.2013.05.001_bb0075","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1463-1326.2008.01018.x","article-title":"Exenatide: a review from pharmacology to clinical practice","volume":"11","author":"Gentilella","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.metabol.2013.05.001_bb0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"10.1016\/j.metabol.2013.05.001_bb0085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/diabetes.51.2.424","article-title":"Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes","volume":"51","author":"Juhl","year":"2002","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.metabol.2013.05.001_bb0090","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/diacare.24.8.1416","article-title":"Glucagon-like peptide-1 infusion must be maintained for 24h\/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment","volume":"24","author":"Larsen","year":"2001","journal-title":"Diabetes Care"},{"issue":"9309","key":"10.1016\/j.metabol.2013.05.001_bb0095","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"issue":"9683","key":"10.1016\/j.metabol.2013.05.001_bb0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"9645","key":"10.1016\/j.metabol.2013.05.001_bb0105","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"issue":"9548","key":"10.1016\/j.metabol.2013.05.001_bb0110","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.metabol.2013.05.001_bb0115","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2337\/diabetes.41.3.368","article-title":"Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance","volume":"41","author":"Van Cauter","year":"1992","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2013.05.001_bb0120","doi-asserted-by":"crossref","first-page":"E871","DOI":"10.1152\/ajpendo.00551.2006","article-title":"Thiazolidinediones improve \u03b2-cell function in type 2 diabetic patients","volume":"292","author":"Gastaldelli","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2013.05.001_bb0125","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1073\/pnas.82.5.1544","article-title":"Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes","volume":"82","author":"Starke","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.metabol.2013.05.001_bb0130","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/diab.20.12.834","article-title":"Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses","volume":"20","author":"Unger","year":"1971","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2013.05.001_bb0135","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2337\/diacare.24.3.539","article-title":"A model-based method for assessing insulin sensitivity from the oral glucose tolerance test","volume":"24","author":"Mari","year":"2001","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2013.05.001_bb0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00125-003-1263-9","article-title":"Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study","volume":"47","author":"Gastaldelli","year":"2004","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.metabol.2013.05.001_bb0145","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus","volume":"25","author":"Vilsb\u00f8ll","year":"2008","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.metabol.2013.05.001_bb0150","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","article-title":"Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes","volume":"30","author":"Kim","year":"2007","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.metabol.2013.05.001_bb0155","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1463-1326.2012.01560.x","article-title":"GLP-1 based therapies: differential effects on fasting and postprandial glucose","volume":"14","author":"Fineman","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"5 Pt 1","key":"10.1016\/j.metabol.2013.05.001_bb0160","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1016\/j.metabol.2013.05.001_bb0165","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-stimulated insulin secretion: effects on \u03b2-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.metabol.2013.05.001_bb0170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.metabol.2013.05.001_bb0175","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of beta-cell function after 3years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.metabol.2013.05.001_bb0180","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.metabol.2013.05.001_bb0185","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1210\/jc.2004-1133","article-title":"beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis","volume":"90","author":"Ferrannini","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2013.05.001_bb0190","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1210\/jc.2010-2146","article-title":"Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects","volume":"96","author":"Cersosimo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2013.05.001_bb0195","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1152\/physrev.1976.56.4.778","article-title":"Physiology and pathophysiology of glucagon","volume":"56","author":"Unger","year":"1976","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/j.metabol.2013.05.001_bb0200","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/en.2004-1349","article-title":"Exenatide (exendin-4) improves insulin sensitivity and \u03b2-cell mass in insulin-resistant obese fa\/fa Zucker rats independent of glycemia and body weight","volume":"146","author":"Gedulin","year":"2005","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.metabol.2013.05.001_bb0205","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni","year":"2011","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.metabol.2013.05.001_bb0210","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00125-012-2738-3","article-title":"Direct effect of GLP-1 infusion on endogenous glucose production in humans","volume":"56","author":"Seghieri","year":"2013","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.metabol.2013.05.001_bb0215","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1210\/jc.2012-1205","article-title":"Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes","volume":"97","author":"Muscelli","year":"2012","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604951300142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604951300142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:02:29Z","timestamp":1758427349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002604951300142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S002604951300142X"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2013.05.001","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2013.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}